echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 3 varieties of the first over-reviewed Omeprazole into the third batch of collection.

    3 varieties of the first over-reviewed Omeprazole into the third batch of collection.

    • Last Update: 2020-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As of July 10, CDE acceptance of consistency evaluation acceptance number of 2202 (526 varieties of 580 enterprises, according to supplementary applications, the same below), has been evaluated acceptance number 603.
    this week (July 3 to July 10) and three more varieties were the first to be evaluated, 35 varieties were awarded, Zhengda Qing and Howson had the first imitation of the competition products.
    the details of the 3 varieties of the first evaluation, the third batch of collection products in the column this week there are 3 varieties of the first through consistency evaluation, respectively, Shandong New Era of Omeprazole intestinal tablets, China Resources Purple Bamboo Pharmaceuticals miso prostotherinol tablets, LunanBet Pharmaceutical's oxytocin Mosabili tablets.
    this week's consistency evaluation of the details table omeprazole intestinal sopranos omeprazole is a proton pump inhibitor, clinically used in the treatment of gastric, duodenal ulcers, reflux esophagitis, zo-Ai syndrome. Developed by AstraZeneca,
    Omeprazole was first listed in Switzerland in 1988, in the United States in 1989, and then in other European countries and Japan.
    the original research manufacturers without intestinal solution tablets.
    it is known that omeprazole was once the world's heavyweight varieties, the market matures, pharmaceutical intelligence data enterprise version of hospital sales statistics, Omeprazole 2019 sample hospital sales of 260 million yuan.
    from the dosage form, intestinal-soluble capsules accounted for the largest proportion, followed by tablets, from the enterprise point of view, Changzhou four drugs, Cornbey, Shandong New Era Pharmaceutical Market share ranked in the top three.
    oral dosage form consistency evaluation of omeprazole is a highly difficult variety, according to the drug registration and acceptance database shows that up to now, Omeprazole intestinal tablets Shandong New Era Pharmaceutical spending for the first enterprise to pass the drug consistency evaluation.
    it is worth mentioning that in the network spread of the country's third batch of 53 varieties of 86 standards of the centralized procurement catalog, Omeprazole oral frequently released agent type in the column, in the third batch of collection is about to start the threshold, Shandong New Era Pharmaceutical Omeprazole tablet first through consistency evaluation, successfully shortlisted for the collection.
    misoprostol tabletmisoprostol is a prostaglandin E1 analogue, mainly used for the prevention and treatment of stomach and duodenal ulcers, developed by Searle (now Pfizer) in 1973, and its tablets were first licensed to market in 1984.
    According to pharmaceutical data, missoprostol tablets 2019 domestic sample hospital sales data of 12.5027 million yuan, of which China Resources Zizhu Pharmaceutical industry accounted for 47.08 percent, Hubei Gedian PeopleFu Pharmaceuticals accounted for 26.28 percent, as shown in the figure: Currently only domestic enterprises Zhejiang Xianyu Pharmaceuticals, Shanghai Xinhua Union Pharmaceuticals, Hubei Gedian People Fu Pharmaceuticals and China Resources Zizhu Pharmaceuticals 4 enterprises have 4 market approvals, three of which have been declared for acceptance of the consistency evaluation of the variety, the first of the varieties of China Resources Zizhu Pharmaceuticals, or will further enhance product competitiveness.
    mosabili tablets Mosabili acid mosabyli for selective 5-serotonin 4 (5-HT4) receptor agonists, clinically used for functional indigestion, esophagus reflux, gastric palsy, constipation and other treatment.
    the original research enterprise for Sumitomo Pharmaceuticals.
    sales of moshabili tablet sample hospital sales in 2019 was 123 million yuan, with Lunanbet having a market share of 44.84 percent.
    at present, the acid Moshabili tablets only Yabao Pharmaceuticals, Haussen Pharmaceuticals, Chengdu Kanghong Pharmaceuticals, Lunanbet Pharmaceuticals, Guangdong Anno Pharmaceuticals 5 enterprises have 5 market approvals.
    one of the Luunanbet Pharmaceuticals and Chengdu Kanghong Pharmaceuticaltwo two enterprises declared consistency evaluation was accepted, now Lunanbet Pharmaceuticals first passed the drug, further enhance the competitive strength of the product, in the next collection of whether it can shine, we wait and see.
    declaration acceptance of 35 products were accepted, Zhengda Qing heavy anti-spitting new drugs were hosted this week CDE added 47 acceptance numbers (35 varieties), from the State Drug Administration officially announced the implementation of consistency evaluation work, injection consistency evaluation declaration acceptance further speed up, this week CDE acceptance of the consistency evaluation acceptance number, according to the dosage form of nearly 75% of the injection stakes, there are 35 varieties of 23.
    in addition, it is worth noting that a number of varieties for this week's first declaration of consistency evaluation of the drug accepted, Zhengda Tianqing, Qilu Pharmaceuticals, Huaren Pharmaceuticals and other enterprises ranked among the heavyweight varieties.
    the first to declare this week accepted the consistency evaluation details of the list, of which, of particular note is the injection of fusapitama double thoramine.
    fusapitin biglutaminamine is a NK1 receptor antagonic, developed by Mersadon (MSD), is a phosphate pre-drug of Aripitan, injected in the body quickly converted into Aripitan, initially approved in the European Union on 10 January 2008, and then in the United States, Japan has been approved, the original research drug is not yet listed in the domestic market, but last year Haussen Pharmaceuticals and The Day qing.
    According to pharmaceutical data, the injection of fusapitin diluenta in September 2015 according to the class 3.1 new drug declaration, after 722 clinical on-site verification, in September 2017 into the priority review, after three rounds of additional information, was approved for listing in October 2019.
    last year, the injection of Fusapitan double-leamine behind Howson Pharmaceuticals was approved, is now the first to declare consistency evaluation, whether can reverse the first imitation of how Hawthorne robbed of the first opportunity, it is worth looking forward to.
    attached: This week's consistency evaluation declaration acceptance details form Note: Red font for the first time this week to declare accepted varieties data source: drug intelligence data, enterprise announcements and other network public data source: drug intelligence network, enterprise announcement and other network public information.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.